Timing is Everything; Tempo Raises Series A

Now that Tempo has raised a $12.1 million Series A round from Polaris, Venrock, Lux Capital and former Biogen Idec Inc. Chairman William Rastetter, PhD, the company is on the way toward solving a tricky drug delivery problem